What is the recommended apixaban (Eliquis) dosage and dosing frequency for stroke prevention in atrial fibrillation, acute deep‑vein thrombosis/pulmonary embolism treatment, and postoperative venous‑thromboembolism prophylaxis?

Eliquis Dosage and Frequency

For stroke prevention in atrial fibrillation, use apixaban 5 mg twice daily as the standard dose, reducing to 2.5 mg twice daily only if the patient meets at least two of three specific criteria: age ≥80 years, weight ≤60 kg, or serum creatinine ≥1.5 mg/dL. 1

Stroke Prevention in Nonvalvular Atrial Fibrillation

Standard Dosing:

• 5 mg orally twice daily for most patients 2, 1

Dose Reduction Criteria:

• 2.5 mg orally twice daily when patients have at least 2 of the following 3 characteristics 2, 1:
  • Age ≥80 years
  • Body weight ≤60 kg
  • Serum creatinine ≥1.5 mg/dL

Critical Pitfall: Approximately 61% of patients receiving reduced-dose apixaban in clinical practice do not actually meet the labeling criteria for dose reduction 3. Patients with only one dose-reduction criterion should receive the full 5 mg twice daily dose, as they demonstrate consistent benefit and safety with this regimen compared to warfarin 4. Inappropriate dose reduction is associated with higher mortality (adjusted HR 1.77) without clear reductions in bleeding risk 3.

Treatment of Acute DVT/PE

Initial Treatment (First 7 Days):

• 10 mg orally twice daily for 7 days 5, 1

Maintenance Treatment (After 7 Days):

• 5 mg orally twice daily 5, 1
• Continue for at least 3-6 months 6, 7

This regimen eliminates the need for parenteral anticoagulation bridging, unlike dabigatran or edoxaban which require 5-10 days of parenteral therapy first 5.

Secondary Prevention of Recurrent VTE

After completing at least 6 months of initial treatment:

• Either 5 mg twice daily OR 2.5 mg twice daily can be used 5, 1

The 2021 ACC Expert Consensus provides conditional recommendation for either dose based on moderate-certainty evidence 5. The AMPLIFY-EXT trial demonstrated that both the treatment dose (5 mg twice daily) and thromboprophylactic dose (2.5 mg twice daily) significantly reduced recurrent VTE compared to placebo (1.7% vs 8.8%, p<0.001) without increasing major bleeding 8. The choice between doses should consider individual bleeding risk versus thrombotic risk.

Postoperative VTE Prophylaxis (Hip/Knee Replacement)

Dosing:

• 2.5 mg orally twice daily 1

Timing and Duration:

• Initial dose: 12-24 hours after surgery 1
• Hip replacement: 35 days total 1
• Knee replacement: 12 days total 1

Important Dosing Adjustments

Drug Interactions: When coadministered with combined P-glycoprotein and strong CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir):

• Reduce 5 mg or 10 mg twice daily doses by 50% 1
• Avoid coadministration if patient already taking 2.5 mg twice daily 1

Renal Considerations: The dose reduction criteria for atrial fibrillation already account for renal dysfunction through the serum creatinine threshold. For dialysis-dependent patients with AF, standard-dose apixaban (5 mg twice daily) showed lower risk of stroke/embolism and death compared to low-dose (2.5 mg twice daily) or warfarin 9.

Administration Considerations

Missed Dose:

• Take as soon as possible on the same day
• Resume twice-daily schedule
• Never double the dose 1

Food Requirements:

• Can be taken with or without food (unlike rivaroxaban which requires food with higher doses) 5

The evidence strongly supports apixaban's efficacy across all three indications, with the ARISTOTLE trial demonstrating superiority over warfarin for stroke prevention (HR 0.79, p<0.001) with significantly less major bleeding (HR 0.69, p<0.001) 2. The simplified dosing without routine monitoring and the ability to initiate treatment without parenteral bridging for VTE represent significant practical advantages 5, 10.